50 results about "Primary tumor site" patented technology

The invention belongs to the cross technical field of veterinary medicine and biomedicine, and relates to a construction and evaluation method of a dog spontaneous breast cancer organoid model, which specifically comprises the following steps: (1) obtaining dog spontaneous breast cancer tissues through operation or biopsy, separating tumor tissues under sterile conditions, and carrying out fine enzymolysis digestion treatment to obtain dog spontaneous breast cancer tissues; obtaining a single-cell suspension; and (2) inoculating the single-cell suspension into a three-dimensional culture system, carrying out three-dimensional culture by adopting a culture medium containing EGF, FGF and B27 in combination with a growth factor, promoting the growth and amplification of the breast cancer organs, and carrying out timely passage according to the growth condition so as to maintain the activity of the model. The model constructed by the invention completely retains genetic heterogeneity and pathological microenvironment of primary tumors, does not need gene editing, is simple and convenient to operate and low in cost, is particularly suitable for individual drug sensitivity detection of pet dogs, and provides an efficient and high-simulation experimental platform for dog breast cancer mechanism research and clinical precise medication.

The application belongs to the technical field of nanomedicine, tumor treatment and immunotherapy, and specifically provides a copper death selective induction nanoparticle targeting tumor mitochondria, which is prepared by the following preparation method: S1, TPY is specifically coupled with MHI through a condensation reaction to obtain MTPY; S2, MTPY is complexed with copper ions to obtain an MTPY-Cu complex; and S3, the MTPY-Cu complex is self-assembled with albumin to form an MTPY-Cu@Alb nanoparticle. The copper dose of the application is only 1 / 1000 of that of free Cu 2+ , and the equivalent immune regulation and killing effects can be achieved; the primary tumor and distant tumor foci can be inhibited, and lung metastasis can be reduced; and the application can induce immune memory and prevent recurrence; the application is combined with cisplatin to significantly enhance the therapeutic effect and reverse the induced immunosuppression; and the application has high biological safety, and has no obvious hepatorenal toxicity or hemolytic reaction.

The application discloses a kind of nanoparticles for tumor sonodynamic combined individualized immunotherapy and its preparation method and application, belong to the field of biological medicine.The nanoparticles for tumor sonodynamic combined individualized immunotherapy are double-shell core structure nanoparticles formed by inner core and shell, and the inner core is formed by self-assembly of TLR3 agonist Poly (I:C), L-arginine and polylysine, and the shell is hyaluronic acid layer HA-Ce6 conjugated with photosensitizer Ce6.It is found through experiment verification that the nanoparticles can target tumor, generate reactive oxygen species to kill tumor cells under the action of ultrasound, promote M1 macrophage polarization and produce NO release at the same time, play the role of antitumor and immune effect, and realize the combined application of sonodynamic and NO gas therapy.The nanoparticles for tumor sonodynamic combined individualized immunotherapy can trigger systemic immune response, inhibit primary tumor, produce immune memory effect, and prevent tumor metastasis and recurrence.

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

This invention discloses a T-cell training method based on tumor organ-on-a-chip. The method includes: preparing an organ-on-a-chip with a micropillar array and a biomimetic fishbone structure; introducing primary tumor cells from a patient into the chip, causing them to spontaneously form uniform three-dimensional tumor spheroids; dynamically pumping pre-activated peripheral blood lymphocytes from the same patient into the chip and co-culturing them with the tumor spheroids; collecting the co-cultured lymphocytes and repeating the co-culture process multiple times to obtain a lymphocyte population with enhanced anti-tumor activity. This invention utilizes organ-on-a-chip technology to highly simulate the dynamic tumor immune microenvironment in vivo. Through multiple cycles of "training," it effectively activates and expands tumor-specific T cells, avoiding immune exhaustion, and providing a highly efficient and controllable new platform for personalized immunotherapy of solid tumors.

The invention provides a conformation-locked amphibian skin peptide derivative or a pharmaceutically acceptable salt thereof. The conformation-locked amphibian skin peptide derivative or the pharmaceutically acceptable salt thereof has a structural formula shown in the specification or a structural analogue thereof, x is derived from one amino acid in TLa, the sequence of the TLa is LLRHVVKILEKYL, and (X) 3 is composed of any continuous sequences in three TLa. The invention also provides a preparation method of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate and an application of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate in tumor immunotherapy. In-vivo experiments show that the conjugate can effectively inhibit primary tumor growth and distal pulmonary metastasis in a melanoma model, and tumors of part of mice can completely fade away. The conjugate disclosed by the invention is expected to be developed into a novel efficient and low-toxicity tumor immunotherapy drug.

The application belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung cancer bone metastasis and application thereof. The main active ingredients of the traditional Chinese medicine composition include, in mass parts, 20-40 parts of radix codonopsis, 20-40 parts of poria, 20-40 parts of astragalus, 10-30 parts of atractylodes, 10-20 parts of licorice, 10-30 parts of curcuma, 10-20 parts of pinellia, 5-10 parts of dried tangerine or orange peel, 20-40 parts of oldenlandia, 10-30 parts of psoralea, 10-30 parts of drynaria, 10-30 parts of epimedium, and 10-20 parts of jackinthepulp. Animal experiments show that the traditional Chinese medicine composition can not only inhibit primary tumor growth, but also slow down tumor progression of bone metastasis. When combined with a chemotherapy drug, the traditional Chinese medicine composition can not only significantly enhance the tumor inhibition effect of the chemotherapy drug, but also significantly prolong the survival time of mice, relieve weight loss and organ toxic side effects caused by the chemotherapy drug.

The invention belongs to the technical field of microorganisms, and particularly discloses an anesthesia coating spore as well as a preparation method and application thereof. The coating spore comprises a spore and a ferric iron-propofol coating attached to the body surface of the spore, and the coating is formed through metal-phenol complexing and pi-pi stacking. The spores are dormant bodies of collagenase-producing bacteria. The coating spores can be selectively germinated and colonized in a tumor hypoxic microenvironment, Fe < 3 + > can promote bacterial proliferation, loaded propofol inhibits tumor metastasis by inhibiting migration and invasion of tumor cells, generated collagenase degrades tumor collagen, meanwhile, Fe < 3 + > is reduced into Fe < 2 + > by glutathione in the cells, and the coating spores can be selectively colonized in the tumor hypoxic microenvironment. Therefore, a powerful Fenton reaction is induced to trigger lipid peroxidation, and ferroptosis of tumor cells is initiated. The injection of the anesthetic coating spores in the single tumor not only effectively ablates the primary tumor and inhibits the growth of the tumor, but also significantly inhibits the distal pulmonary metastasis of the in-situ tumor model.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The invention relates to the technical field of biomedical engineering, and discloses a human-derived premature colorectal tumor organoid and a culture method and application thereof, and the culture method comprises the following steps: obtaining a fresh tumor tissue sample of a premature colorectal cancer patient of which the onset age is less than 50 years old; digesting the pretreated tissue blocks for 30 to 60 minutes by using digestive juice containing type IV collagenase; mixing the digested cell suspension and matrigel according to a volume ratio of 1: 1 to 1: 1.5; embedding the mixture into a culture plate, and adding a colorectal tumor organoid culture medium for culture after gel formation. Aiming at the special biological characteristics of the early-onset colorectal cancer tissue, a differentiated digestion strategy of combination of type IV collagenase and DNase I is adopted, so that the organoid formation rate is remarkably improved, the cultured organoid keeps high molecular consistency with the primary tumor, stable passage can be realized, and the culture cost is reduced. And a reliable in-vitro model platform is provided for mechanism research and drug screening of the premature colorectal cancer.

The application provides a bicyclic compound with a structure shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a prodrug molecule thereof, a pharmaceutical composition and application. The compound provided by the application can activate CD137, enhance the immune function of cytotoxic T lymphocytes (CTL), enhance the memory function of CD8+ T cells and CD4+ T cells, can make the polarization of CD4+ T cells tilt to a state beneficial to cellular immunity, and can promote the multimerization of CD137, so that T cell immunity can be effectively activated, the volume of a primary tumor can be effectively reduced, and the compound can be used for inhibiting and treating tumors.

The invention relates to an application of India giant globular bacteria in preparation of a medicine for regulating a tumor microenvironment, and belongs to the technical field of biological medicines. The invention provides an application of India giant globular bacteria XA-511 in preparation of a medicine for regulating a tumor microenvironment. Researches show that the India giant globular bacteria XA-511 can be colonized in a tumor microenvironment, the tumor microenvironment can be transformed through a metabolic pathway of the India giant globular bacteria XA-511, immune cell activation enhancement and the like, and cold tumors are transformed into hot tumors, so that the treatment effect of the immunosuppressor on tumors is promoted. Furthermore, treatment of secondary tumors is more difficult than primary tumors, since tumors may be present at multiple sites, and the volume and number of tumors may vary over time. And by virtue of the characteristic of a tumor hypoxia environment, the India giant globular bacteria XA-511 can be selectively colonized at a tumor occurrence part after entering a systemic circulatory system, so that the tumor microenvironment is specifically changed, and the treatment effect of the immunosuppressor on tumors is enhanced.

The invention discloses a construction and evaluation method of an Rb1 and Trp53 (p53) double-gene mutation mouse spontaneous lung cancer organoid model, and the construction method comprises the following steps: separating lung cancer tissues under a sterile condition, and carrying out fine enzymolysis digestion treatment to obtain a single-cell suspension; inoculating the single-cell suspension into a three-dimensional culture system, carrying out three-dimensional culture by adopting a culture medium containing EGF, FGF and B27 in combination with growth factors, promoting the growth and amplification of lung cancer organs, and carrying out timely passage according to the growth condition to maintain the activity of the model; the model constructed by the invention completely retains genetic heterogeneity and pathological microenvironment of the primary tumor, in-vitro gene editing is not needed, the operation is simple and convenient, the cost is low, and an efficient and high-simulation experimental platform is provided for lung cancer mechanism research and individualized drug screening.

Disclosed herein are compositions and methods for deploying interventional agents into constrained biological states using non-crystalline amorphous iron oxide nanoparticles (NAIONPs). The NAIONPs comprise coordination-stabilized, aqueous colloidal dispersions lacking long-range crystalline order and presenting surface-accessible coordination sites for reversible or covalent association with one or more interventional agents. The compositions are configured to modify the biological context in which an interventional agent is presented, enabling functional engagement of agents whose deployment is limited when administered in isolation due to factors including impaired biodistribution, reduced stability, stress sensitivity, immune-mediated clearance, altered cellular responsiveness, or non-optimal exposure conditions. Interventional agents may include polynucleotides, peptides, proteins, small molecules, targeting moieties, radiologic agents, or combinations thereof. The disclosed compositions and methods are applicable to in vivo, ex vivo, and in vitro biological systems, including oncologic disease states such as primary tumors, metastatic disease, hematologic malignancies, and treatment-refractory cancers.

This invention discloses a method and application for constructing personalized organoids for multiple myeloma based on stiffness gradient regulation, belonging to the field of biomedical technology. The method includes the following steps: S1: mixing patient bone marrow plasma with a calcium-containing crosslinking agent to form a gelatable precursor; S2: combining the gelatable precursor with a three-dimensional gelatin scaffold having a stiffness gradient (Young's modulus of 25-50 kPa) to construct a three-dimensional microenvironment simulating the stiffness gradient of bone marrow; S3: gelling the precursor to form a hydrogel-scaffold composite system encapsulating target cells; S4: seeding vascular endothelial cells onto the surface of the composite system to simulate a vascular niche structure. The organoid model for multiple myeloma constructed by this invention, based on the patient's autologous bone marrow plasma and possessing stiffness gradient characteristics, can effectively simulate the bone marrow mechanical microenvironment and preserve key components of the tumor microenvironment, supporting the long-term growth of primary tumor cells and improving the accuracy of drug sensitivity prediction.

The present application relates to the technical field of rectal cancer CTV segmentation, in particular to a rectal cancer CTV segmentation method based on CViL-UNet, comprising the following steps: preprocessing rectal cancer CT image data, converting a 3D CT sequence into a multi-channel 2D input format, removing image noise and intensity non-uniformity, and standardizing the pixel value range to adapt to the CViL-UNet model input. The present application realizes accurate identification of the key areas of CTV primary tumor, subclinical spread area and micro-infiltration focus through local-global feature cooperation and high-frequency detail enhancement, solves the pain points of missing micro-infiltration and misjudging healthy tissue in traditional methods, can process conventional CT images without intestinal preparation, breaks the dependence of traditional methods on ideal image conditions, and the automatic and real-time segmentation process in clinical value eliminates the subjectivity and inefficiency caused by manual intervention, while meeting the dual requirements of millimeter-level precision and rapid deployment for radiotherapy planning.

Provided are conjugates that can be used for insitu cancer vaccination, such as for cancers with limited accessibility (e.g., lung cancer, pancreatic cancer, renal cancer, etc.) and metastatic disease in situations where the primary tumor has been surgically resected.SOLUTION: Provided are complexes comprising a knottin peptide comprising a modified loop that binds to a cell surface molecule and an immunostimulatory agent conjugated to the knottin peptide via a linker. In some embodiments, the immune stimulating agent activates a pathogen recognition receptor (PRR). For example, the immunostimulatory agent can be a toll-like receptor (TLR) agonist, e.g., an agonist of TLR7, TLR8, and / or TLR9. Also provided are compositions (e.g., pharmaceutical compositions) comprising the complexes of the disclosure, as well as kits comprising such compositions and methods of using such compositions, e.g., to treat an individual having cancer.SELECTED DRAWING: Figure 1

This invention relates to an animal model of mediastinal lymph node metastasis in lung cancer and its construction method. The core of this invention lies in the precise intrapulmonary in situ microinjection technique to directly implant human lung cancer cells into the lung parenchyma of immunodeficient mice. Utilizing the natural lymphatic drainage pathway of the lung tissue, tumor cells are induced to migrate to the mediastinal lymph nodes, thus successfully constructing a complete metastasis chain model from the primary tumor to regional lymph nodes. This model can more realistically simulate the microenvironment and process of lung cancer lymph node metastasis, and is suitable for metastasis mechanism research, drug evaluation, and the development of personalized treatment strategies, possessing high translational medicine value.

The present disclosure is directed to a method that involves selecting a subject having a primary tumor and obtaining, from the selected subject, a sample containing exosomes derived from primary tumor cells. The exosomes are isolated from the sample and expression levels of cell migration-inducing and hyaluronan-binding protein (CEMIP) are detected in the isolated exosomes.

The invention belongs to the field of new application of medicines, and particularly relates to application of Sivelestat in preparation of cancer radiotherapy adjuvant medicines. According to the invention, Sivelestat which has been used for acute respiratory distress syndrome is creatively applied to tumor radiotherapy, and the Sivelestat inhibits the activity of neutrophil elastase and effectively blocks the formation of a neutrophil outer trapping net induced by radiotherapy, so that the invasion of tumor cells and the abnormal generation of blood vessels are inhibited, and an immunosuppression microenvironment is established. The application not only maintains the local killing effect of radiotherapy on primary tumors, but also cuts off the key path from radiotherapy to NETs to metastasis from the mechanism, and significantly reduces the risk of tumor recurrence and distant metastasis after radiotherapy. The traditional Chinese medicine composition has the transformation advantage of new use of old medicines, is clear in clinical safety, and is suitable for adjuvant therapy of various solid tumors.

The invention relates to a composition for blocking lactic acid efflux and enhancing tumor photoimmunotherapy as well as a preparation method and application of the composition, and the composition co-delivers an MCT4 inhibitor cyclostin and a photodiagnosis and treatment agent L8BO through a lactic acid metabolism checkpoint blocking strategy of a targeted monocarboxylic acid transporter 4 (MCT4) so as to enhance photoimmunotherapy. The composition L8-atSY has a strong intramolecular charge transfer effect, an optimized singlet-triplet energy gap and an excellent light capture capability, realizes simultaneous generation of I-type and II-type active oxygen, has a total active oxygen yield up to 503 times within the illumination time of 5 minutes, and also has photothermal conversion efficiency up to 46.2%. Under the trigger of lactic acid efflux blocking induction intracellular acidification, the nanoparticles based on the composition show an excellent tumor inhibition effect, almost completely inhibit primary tumors (the inhibition rate is 99.6%), significantly inhibit distal tumors (the inhibition rate is 68.6%), and reduce pulmonary metastasis at the same time.

This invention relates to the field of artificial intelligence in oncology medicine, specifically disclosing a system for quantifying residual tumor burden in gastric cancer, comprising: a data acquisition and interaction terminal, an AI core computing center, and a clinical precision decision support platform; the data acquisition and interaction terminal is configured to acquire in parallel high-resolution digital pathological slides of patients after surgery, continuous physiological time-series characteristic sequences after surgery, and the molecular expression abundance of POU4F1 transcription factor and TGF-β signaling pathway in tumor tissue; the AI ​​core computing center includes a three-dimensional quantification unit for pathological images, a dynamic correction unit for physiological homeostasis, and a molecular phenotypic decision unit; the three-dimensional quantification unit for pathological images is used to automatically segment and obtain the geometric mean diameter of the primary tumor bed, the proportion of residual tumor in the primary lesion, the number of positive lymph nodes, and the proportion of residual tumor in the worst-regressed lymph nodes; the technical solution of this invention can solve the problems of coarse quantification and large subjective bias.

The invention discloses a macaque skin squamous carcinoma cell line MCSCC14397 and application of the macaque skin squamous carcinoma cell line MCSCC14397. The macaque skin squamous carcinoma cell line is named as macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC (China Center For Type Culture Collection) NO: C2025156. The cell line disclosed by the invention has similar protein expression with primary tumor tissues, has chromosome abnormal karyotype, in-vitro tumor formation capability and stable proliferation characteristics, and simultaneously shows remarkable genome instability (such as high-frequency Cgt, T mutation and structural variation) and inflammation signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage reaction and inflammatory factor expression, and unique advantages are provided for application of the cell line in skin squamous cell carcinoma mechanism research, drug screening and drug efficacy evaluation. The cell line disclosed by the invention can be used as an effective cell model, can be used for establishing a xenotransplantation animal model, and can provide a research basis for deeply researching the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous cell carcinoma as well as innovative drug development and screening.

This invention provides a stable passaged human mesothelioma cell line MESO-016, its construction method, and its application in tumor research and drug development. The cell line provided by this invention can be continuously passaged in vitro and possesses xenogeneic tumorigenesis ability. Tumors formed in nude mice exhibit the same pathological characteristics as the primary tumor tissue, making it suitable as a cell material for research on mesothelioma-related drugs and diagnostic reagents, as well as for studying the mechanisms of tumor development and progression.

The invention discloses a construction method and application of a refractory pituitary tumor organ. The method comprises the following steps: culturing pituitary tumor tissues by using a pituitary tumor organoid culture medium, the pituitary tumor organoid culture medium comprises a basic culture medium and an additive, and the additive comprises triiodothyronine and / or thyroid stimulating hormone releasing hormone. The organoid constructed by the method can stably express pituitary tumor markers such as SF1 / FSH / synapsin and accurately simulate clinical drug resistance characteristics (such as temozolomide resistance) in vitro, solves the problems that primary tumor cells are low in activity and drug resistance phenotypes are difficult to maintain, fills the blank that no reliable in-vitro model exists in the field, and has good application prospects. And a platform is provided for drug resistance mechanism research and individualized drug screening.

The application provides a double-layer biomimetic microneedle drug release system and a preparation method thereof, and belongs to the technical field of biological medicines.The application realizes programmed sequential release of inner-layer and outer-layer drugs by designing different properties of the inner-layer and outer-layer microneedle carrier materials.The application enhances the adhesion and hemostatic effect of the microneedle drug release device on the liver wound surface by designing a double-layer mushroom-shaped microneedle structure, improves the water solubility of hydrophobic therapeutic drugs by introducing drug-loaded particles, so that the therapeutic drugs can be used locally, and uses the microneedle to deliver the therapeutic drug-loaded particles to the disease tissue.Compared with traditional adjuvant therapy for preventing recurrence of liver primary tumors, the programmed sequential drug release device based on the microneedle can realize direct delivery of drugs to potential metastatic lesions, and avoids systemic adverse reactions caused by oral administration.Compared with local treatment methods such as transhepatic arterial intervention embolization and local radiotherapy, the double-layer biomimetic microneedle drug release system has the advantages of high targeting, small toxic and side effects, and convenient operation.

The application discloses a rhesus monkey skin squamous carcinoma cell line MCSCC14397 and application thereof. The rhesus monkey skin squamous carcinoma cell line is named as the rhesus monkey skin squamous carcinoma cell line MCSCC14397, and the preservation number is CCTCC NO: C2025156. The cell line of the application has similar protein expression as primary tumor tissue, has abnormal karyotype, in-vitro tumorigenic ability and stable proliferation characteristics, and simultaneously shows significant genomic instability (such as high-frequency C>T mutation, structural variation) and inflammation signal activation. MYO10 gene expression is up-regulated in the cell line and drives DNA damage response and inflammation factor expression, which provides unique advantages for the application of the cell line in skin squamous carcinoma mechanism research, drug screening and efficacy evaluation. The cell line of the application can be used as an effective cell model, can establish a xenotransplantation animal model, and can provide a research basis for in-depth research on the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous carcinoma and innovative drug development and screening.

The invention relates to the technical field of tumor treatment, and discloses a tumor mechanical environment recoding nano-carrier as well as a preparation method and application thereof. The tumor mechanical environment recoding nano-carrier designed by the invention comprises a tumor-targeted overexpressed swell-labeled ligand, manganese dioxide with response to an acidic tumor microenvironment (TME), an LDHA inhibitor for inhibiting the generation of lactic acid, and polydopamine modified gold nanoparticles. The tumor mechanical environment recoding nano-carrier which is reasonably designed can synchronously regulate metabolism (lactic acid inhibition) and immune response (cGAS-STING pathway activation), remodeling is carried out according to biomechanical characteristics (such as hardness and permeability) of a tumor mechanical microenvironment, and multi-dimensional coordinated regulation of metabolism, immunity and biomechanics is realized; the synergistic effects significantly enhance the immunotherapy effect, reverse radiation resistance and trigger systemic immune response, and have significant curative effects on primary and distant tumors.